CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 180 enrolled
Drug / intervention
axitinib +4 moredrug
Likely dose
axitinib 5mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00768755
NCT00768755Phase 2Completed
CompareCT.gov

Randomized Phase 2 Study Of Cisplatin/Pemetrexed With Or Without Axitinib (AG-013736) As First-Line Treatment For Patients With Non-Squamous Non-Small Cell Lung Cancer

Pfizer·interventional·Posted Oct 8, 2008·Updated Oct 28, 2015

In Brief

A Phase 2 clinical trial evaluating axitinib and chemotherapy for Carcinoma, Non-Small Cell Lung. Completed, enrolled 180 participants across 52 sites in 11 countries.

Detailed Summary

AG-013736 (axitinib) in combination with cisplatin and pemetrexed will be evaluated as first-line treatment of patients with locally advanced, recurrent, or metastatic non-squamous, non small cell lung cancer (NSCLC).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCarcinoma, Non-Small Cell Lung
CountriesItaly, Japan, Poland, Romania, Russia, Spain, Switzerland, Taiwan, Ukraine, United Kingdom, United States
Collaborators--

Timeline

Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedOct 8, 2008
Enrollment StartJan 1, 2009
Primary CompletionMar 1, 2011
Study CompletionMar 1, 2012
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 17.7 years ago

Interventions

axitinibdrug

5mg BID po up to max 10mg BID po

axitinibdrug

5mg BID po up to max 10mg BID po paused for 3 days before each cycle of concomitant chemotherapy

chemotherapydrug

Pemetrexed(500mg/m2)/Cisplatin(75mg/m2) x max 6 cycles

axitinibdrug

5mg BID po up to max 10mg BID po paused before each concomitant chemotherapy

chemotherapydrug

Pemetrexed(500mg/m2)/Cisplatin(75mg/m2) x max 6 cycles